新生儿早发型脓毒症风险管理:基于概率的方法及近期文献评估:瑞士新生儿学会与瑞士儿科感染病学组国家指南更新
该指南由瑞士新生儿学会与瑞士儿科感染病学组基于文献批判性综述更新,提出对早发型脓毒症(EOS)风险新生儿采用基于概率的管理策略。足月及晚期早产儿EOS发生率约1/3000–1/5000、病死率约3%,极早产儿更高;而疑似EOS的抗生素暴露比例过高。指南明确有感染性休克临床征象时立即使用抗生素,无EOS征象者不用抗生素,不推荐使用EOS计算器,血培养≥1 ml且24–36 h无生长可停药,不推荐PCR作为标准方法,生物标志物不作为启动或停用抗生素的标准决策依据。
要点
- 有感染性休克临床征象的新生儿应立即使用抗生素;无任何提示EOS临床征象的新生儿不应使用抗生素。
- 对所有有EOS风险因素的新生儿推荐系列体格检查;孤立的呼吸急促或择期剖宫产分娩后立即出现的呼吸窘迫可能提示脓毒症概率低。
- 开始抗生素前应采血培养,单瓶需氧瓶最小采血量1 ml;24–36 h血培养无病原体检出可停用抗生素。
- 瑞士不推荐使用EOS计算器,因在该抗生素暴露率低于3%的人群中影响不明确。
- 血培养证实的EOS、危重病情或存在神经系统症状(如惊厥或意识改变)时推荐腰椎穿刺。
适用人群与场景
- 适用于有EOS风险的新生儿,包括足月及晚期早产儿(EOS发生率约1/3000–1/5000,病死率约3%)和极早产儿(EOS发生率及病死率显著更高)。
- 在瑞士及其他高收入国家背景下,疑似EOS的抗生素暴露比例与EOS实际发生率相比过高。
诊断标准与关键阈值
- 不推荐使用EOS计算器作为风险分层工具(瑞士指南明确不推荐),因在该抗生素暴露率低于3%的人群中影响不明确。
- 孤立的呼吸急促或择期剖宫产分娩后立即开始的呼吸窘迫,或临床征象有明确的其他解释而非EOS,可能提示脓毒症概率低。
- 不明原因的早产合并风险因素具有内在较高的EOS风险。
处置流程与药物剂量
- 有感染性休克临床征象时立即给予抗生素。
- 经验性治疗首选阿莫西林联合氨基糖苷类。
- 对所有有EOS风险因素的新生儿进行系列体格检查。
- 无任何提示EOS临床征象的新生儿不应使用抗生素。
- 并非所有呼吸窘迫新生儿都应经验性使用抗生素。
- 开始抗生素治疗前采血培养,单瓶需氧血培养瓶最小采血量1 ml;若24–36 h血培养无病原体检出可停用抗生素。
- 不推荐以PCR为基础的血液病原体检测作为标准方法。
- 血培养证实的EOS、危重病情或存在神经系统症状(如惊厥或意识改变)时推荐腰椎穿刺。
红旗征与不能漏的情况
- 感染性休克临床征象:应立即给予抗生素。
- 乳酸升高:可能提示灌注不良,需全面评估临床状况。
- 惊厥或意识改变等神经系统症状:推荐腰椎穿刺。
研究设计与关键结果
- 该指南由瑞士新生儿学会与瑞士儿科感染病学组制定,基于对文献的批判性综述更新,提出基于概率的EOS管理方法。
- 背景数据:足月及晚期早产儿EOS发生率约1/3000–1/5000,病死率约3%;极早产儿EOS发生率及病死率显著更高;疑似EOS的抗生素暴露比例过高,带来未来健康及抗菌药物耐药(AMR)后果。
- 推荐要点:有感染性休克征象立即使用抗生素;无EOS临床征象者不使用抗生素;不推荐EOS计算器(瑞士抗生素暴露率低于3%);血培养单瓶需氧瓶最小1 ml,24–36 h无生长可停药;不推荐PCR作为标准方法;腰椎穿刺用于血培养证实的EOS、危重病情或神经系统症状;生物标志物不作为标准决策依据;EOS概率低时24 h内尽早停药。
证据类型、等级与局限
- 证据类型:国家指南(瑞士新生儿学会与瑞士儿科感染病学组),基于文献批判性综述制定。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对无EOS临床征象的新生儿不应使用抗生素,以减少不必要的抗生素暴露及抗菌药物耐药。
- 有感染性休克临床征象时立即使用抗生素,不应等待血培养结果。
- 开始抗生素前应采血培养(单瓶需氧瓶,最小1 ml),以支持24–36 h无病原体检出时停用抗生素。
- 瑞士不推荐使用EOS计算器进行风险分层。
- 不推荐以PCR为基础的血液病原体检测作为标准方法。
- 生物标志物不用于标准决策,但可在算法中、对医疗团队适当培训后使用。
- 临床征象有明确其他解释(如择期剖宫产分娩后立即出现的呼吸窘迫、孤立性呼吸急促)时,可能提示脓毒症概率低,并非所有呼吸窘迫新生儿都需经验性抗生素。
指南或共识出处
- 指南名称:Management of neonates at risk of early onset sepsis: a probability-based approach and recent literature appraisal : Update of the Swiss national guideline of the Swiss Society of Neonatology and the Pediatric Infectious Disease Group Switzerland(新生儿早发型脓毒症风险管理:基于概率的方法及近期文献评估:瑞士新生儿学会与瑞士儿科感染病学组国家指南更新)。
- 发布机构:瑞士新生儿学会(Swiss Society of Neonatology)与瑞士儿科感染病学组(Pediatric Infectious Disease Group Switzerland)。
- 期刊:Eur J Pediatr。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: In Switzerland and other high-income countries, one out of 3000 to 5000 term and late preterm neonates develops early onset sepsis (EOS) associated with a mortality of around 3%, while incidence and mortality of EOS in very preterm infants are substantially higher. Exposure to antibiotics for suspected EOS is disproportionally high compared to the incidence of EOS with consequences for future health and antimicrobial resistance (AMR). A safe reduction of unnecessary antibiotic treatment has to be a major goal of new management strategies and guidelines. Antibiotics should be administered immediately in situations with clinical signs of septic shock. Group B streptococcus (GBS) and Escherichia coli (E. coli) are the leading pathogens of EOS. Amoxicillin combined with an aminoglycoside remains the first choice for empirical treatment. Serial physical examinations are recommended for all neonates with risk factors for EOS. Neonates without any clinical signs suggestive of EOS should not be treated with antibiotics. In Switzerland, we do not recommend the use of the EOS calculator, a risk stratification tool, due to its unclear impact in a population with an observed antibiotic exposure below 3%. Not all neonates with respiratory distress should be empirically treated with antibiotics. Isolated tachypnea or respiratory distress starting immediately after delivery by elective caesarean section or a clearly assessed alternative explanation than EOS for clinical signs may point towards a low probability of sepsis. On the other hand, unexplained prematurity with risk factors has an inherent higher risk of EOS. Before the start of antibiotic therapy, blood cultures should be drawn with a minimum volume of 1 ml in a single aerobic blood culture bottle. This standard procedure allows antibiotics to be stopped after 24 to 36 h if no pathogen is detected in blood cultures. Current data do not support the use of PCR-based pathogen detection in blood as a standard method. Lumbar puncture is recommended in blood culture-proven EOS, critical illness, or in the presence of neurological symptoms such as seizures or altered consciousness. The accuracy of a single biomarker measurement to distinguish inflammation from infection is low in neonates. Therefore, biomarker guidance is not a standard part of decision-making regarding the start or stop of antibiotic therapy but may be used as part of an algorithm and after appropriate education of health care teams. Every newborn started on antibiotics should be assessed for organ dysfunction with prompt initiation of respiratory and hemodynamic support if needed. An elevated lactate may be a sign of poor perfusion and requires a comprehensive assessment of the clinical condition. Interventions to restore perfusion include fluid boli with crystalloids and catecholamines. Neonates in critical condition should be cared for in a specialized unit. In situations with a low probability of EOS, antibiotics should be stopped as early as possible within the first 24 h after the start of therapy. In cases with microbiologically proven EOS, reassessment and streamlining of antibiotic therapy in neonates is an important step to minimize AMR.
CONCLUSION: This guideline, developed through a critical review of the literature, facilitates a probability-based approach to the management of neonates at risk of early onset sepsis.
WHAT IS KNOWN: • Neonatal exposure to antibiotics is disproportionally high compared with the incidence of early onset sepsis with implications for future health and antimicrobial resistance.
WHAT IS NEW: • A probability-based approach may facilitate a more balanced management of neonatal sepsis and antibiotic stewardship.
参考来源
- Stocker M, Rosa-Mangeret F, Agyeman PKA, et al. Management of neonates at risk of early onset sepsis: a probability-based approach and recent literature appraisal : Update of the Swiss national guideline of the Swiss Society of Neonatology and the Pediatric Infectious Disease Group Switzerland. Eur J Pediatr. 2024. PMID: 39417838. doi:10.1007/s00431-024-05811-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。